ir.akersbiosciences.com ir.akersbiosciences.com

ir.akersbiosciences.com

Investor Relations | Akers Biosciences, Inc.

The Investor Relations website contains information about Akers Biosciences, Inc. business for stockholders, potential investors, and financial analysts.

http://ir.akersbiosciences.com/

WEBSITE DETAILS
SEO
PAGES
SIMILAR SITES

TRAFFIC RANK FOR IR.AKERSBIOSCIENCES.COM

TODAY'S RATING

>1,000,000

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

December

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Tuesday

TRAFFIC BY CITY

CUSTOMER REVIEWS

Average Rating: 4.1 out of 5 with 8 reviews
5 star
3
4 star
3
3 star
2
2 star
0
1 star
0

Hey there! Start your review of ir.akersbiosciences.com

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

Desktop Preview Tablet Preview Mobile Preview

LOAD TIME

0.4 seconds

FAVICON PREVIEW

  • ir.akersbiosciences.com

    16x16

CONTACTS AT IR.AKERSBIOSCIENCES.COM

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

CONTENT

SCORE

6.2

PAGE TITLE
Investor Relations | Akers Biosciences, Inc. | ir.akersbiosciences.com Reviews
<META>
DESCRIPTION
The Investor Relations website contains information about Akers Biosciences, Inc. business for stockholders, potential investors, and financial analysts.
<META>
KEYWORDS
1 investor relations
2 technologies
3 about abi
4 news
5 nasdaq aker
6 lse akr l
7 intra
8 press releases
9 events and presentations
10 corporate governance
CONTENT
Page content here
KEYWORDS ON
PAGE
investor relations,technologies,about abi,news,nasdaq aker,lse akr l,intra,press releases,events and presentations,corporate governance,board of directors,committee composition,contact the board,insider ownership,insider transactions,sec filings,briefcase
SERVER
Microsoft-IIS/6.0
POWERED BY
ASP.NET
CONTENT-TYPE
utf-8
GOOGLE PREVIEW

Investor Relations | Akers Biosciences, Inc. | ir.akersbiosciences.com Reviews

https://ir.akersbiosciences.com

The Investor Relations website contains information about Akers Biosciences, Inc. business for stockholders, potential investors, and financial analysts.

SOCIAL ENGAGEMENT



OTHER SITES

ir.aimmune.com ir.aimmune.com

Investor Overview - Investor Relations - Aimmune

CODIT and Oral Immunotherapy. AR101 for Peanut Allergy. Stock Quote and Chart. Aimmune Therapeutics a 35th Annual J.P. Morgan Healthcare Conference. 160;at 5:00 pm PT. Aimmune Therapeutics a 35th Annual J.P. Morgan Healthcare Conference. Wednesday, January 11, 2017 . 5:00 pm PT  . Click here for webcast. Click here to add this event to your calendar. January 4, 2017. Aimmune Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference. December 1, 2016. Aimmune Therapeutics Appoints Scien...

ir.airberlin.com ir.airberlin.com

airberlin IR – Investor Relations

Creditor Relations - Anleihen. Raquo; Investor Relations. Airberlin-Aktie, XETRA: 0,04 EUR, 29.03.2018, 17:35. Creditor Relations - Anleihen. Geplanter Erwerb der NIKI Luftfahrt GmbH durch die Deutsche. NIKI Luftfahrt GmbH hat Antrag auf Eröffnung eines. Geplanter Erwerb der NIKI Luftfahrt GmbH durch die Deutsche.

ir.airmedia.net.cn ir.airmedia.net.cn

AirMedia Group Inc. - Investor Relations - Investor Relations Home

Stock Quote and Chart. Press Releases and Events. First Quarter 2015 Unaudited Financial Results. AirMedia 2014 20-F Filing. AirMedia Special Committee Appoints Advisors. AirMedia Announces Receipt of Preliminary Non-Binding "Going Private" Proposal. AirMedia Reaches Definitive Agreement to Sell 75% Equity Interest of its Advertising Business for RMB2.1 Billion. AirMedia Obtains Wi-Fi Concession Right on Ordinary Trains Operated by Beijing Railway Bureau. There are currently no events scheduled. 15/F, Sk...

ir.akamai.com ir.akamai.com

Investors Home | Investor Relations | Akamai

Skip to main content. State of the Internet. Web and Mobile Performance. Akamai is the global leader in Content Delivery Network (CDN) services, making the internet fast, reliable and secure for its customers. The company’s advanced web performance, mobile performance, cloud security and media delivery solutions are revolutionizing how businesses optimize consumer, enterprise and entertainment experiences for any device, anywhere. Learn about our commitment to responsible corporate governance. US Toll Fr...

ir.akebia.com ir.akebia.com

Investors - Akebia Therapeutics

ELEVATION 5,250 ft. HIF regulation could have therapeutic uses across a variety of conditions. We are a biopharmaceutical company focused on the development of novel proprietary therapeutics based on hypoxia inducible factor, or HIF, biology and the commercialization of these products for patients with kidney disease. Aug 11, 2015. Akebia Announces Second Quarter 2015 Financial Results. Jun 16, 2015. Akebia to Present at the 2015 JMP Securities Life Sciences Conference. View all press releases ».

ir.akersbiosciences.com ir.akersbiosciences.com

Investor Relations | Akers Biosciences, Inc.

The Company is incorporated in the United States in the State of New Jersey where all corporate operations currently reside. The rights of shareholders may be different from the rights of shareholders in a UK incorporated company. There are no restrictions on the trading of ABI's shares on AIM . Day High: 3.86. Day Low: 3.77. Aug 14, 2015. Delayed 20 min., by eSignal. Day High: 245.25. Day Low: 245.00. Aug 14, 2015. Delayed 20 min., by eSignal. Aug 14, 2015. Aug 13, 2015. View all press releases ».

ir.akvagroup.com ir.akvagroup.com

Investor Relations - Investor Relations

Your partner in aquaculture technology. AKVA group is the global leader in delivering technology to the aquaculture industry. The shares of AKVA group are traded on the Oslo Stock Exchange from November 2006. The company will strive to provide the market with relevant information according to the current regulations. It will always be an objective to give correct, relevant and timely information to all market participants at the same time. AKVA group ASA : 1Q 2015 financial reporting. Tel 47 916 39 831.

ir.albint.com ir.albint.com

Investor Relations - Investor Relations - Albany International Corp.

Q2 2015 Albany International Corp Earnings Conference Call. 160;at 9:00 am ET. Q2 2015 Albany International Corp Earnings Conference Call. Wednesday, August 5, 2015 . 9:00 am ET  . Click here for webcast. Click here to add this event to your calendar. Q3 2014 Albany International Corp Earnings Conference Call. Tuesday, November 4, 2014 9:00 am ET. Q3 2014 Financial Results. Q3 2014 Earnings Call Presentation. Albany International Reports Second-Quarter Results. Tuesday, August 4, 2015 - 5:00 pm. Replicat...

ir.aldeyra.com ir.aldeyra.com

Investors - Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics is a clinical-stage biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous free aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2, a product candidate designed to trap free aldehydes. Aldeyra has initiated clinical testing of NS2 for the treatment of Sjögren-Larsson Syndrome and noninfectious anterior uveitis. Aldeyra Therapeutics Corporate Presentation - August 2015. Aldeyra ...

ir.alexionpharm.com ir.alexionpharm.com

Alexion Pharmaceuticals, Inc. - Investor Relations

Europe, the Middle East and Africa. Sponsored Research and Collaborations. Last $ 189.62. 080715 4:00 PM ET. Alexion Pharmaceuticals to Report Second Quarter 2015 Results on Thursday, July 30, 2015. Thu, 30 Jul, 2015 - 10:00 AM ET Listen to Webcast ». 2Q 2015 Earnings Slides. Please see Full Prescribing Information. And Important Safety Information.

ir.algodongroup.com ir.algodongroup.com

Algodon Wines & Luxury Development Group, Inc.

Algodon Wine and Luxury Development Group. How to Invest with Us. Algodon Uncorks Preview of 2015 Wine Line and New Blend for Chinese Market. Dec 16, 2014. Located in the city's most elegant residential neighborhood of Recoleta, as well as the Mendoza wine resort called Algodon Wine Estates. Sign up for email alerts. Be the first to receive breaking news. All Securities offered through DPEC Capital, Inc. (Member FINRA.